Alzheimer's and Parkinson's charities identify new ways to reuse current drugs
This method of drug development could also reduce the time patients are left waiting for new treatments by up to 10 years, they added.
It comes after the NHS spending watchdog rejected the use of new Alzheimer's drugs lecanemab and donanemab for widespread use in the health service.
The drugs were approved for use in the UK last year by the UK's medicines regulator but the NHS spending watchdog, the National Institute for Health and Care Excellence (Nice), said they could not be used in the NHS because the benefits are 'too small' to justify the cost.
Now charities Cure Parkinson's and Alzheimer's Research UK have joined forces to find current drugs that may tackle some of the common biology behind both diseases.
https://x.com/AlzResearchUK/status/1929856926885539966/photo/2
After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson's over a decade ago, experts from both fields will select the most promising drugs for both Parkinson's and dementia, so they can be moved quickly into clinical trials.
Weight loss jabs are already being investigated for their effectiveness in treating symptoms of both diseases and experts hope to uncover more drugs that can have multiple uses.
Semaglutide, the active ingredient for weight loss and diabetes drugs Wegovy and Ozempic, is being examined in clinical trials to see whether it can help patients with Alzheimer's disease or Parkinson's.
Trial results for the Alzheimer's trial are expected to be published later this year.
Dr Sheona Scales, director of research at Alzheimer's Research UK, told the PA news agency that the iLCT project had already been 'hugely successful' with people who have Parkinson's, adding: 'Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process.
'What we wanted to do is to build on their knowledge and experience and expertise in order to be able to bring a process similar to that to Alzheimer's disease.'
Dr Scales said that there are some 'common grounds' between Parkinson's and Alzheimer's – both are neurodegenerative diseases and have some 'common biological processes' – such as inflammation, mitochondrial dysfunction and 'protein misfolding' – which could be targets for repurposed drugs.
'Getting multiple drugs that are targeting the disease is really important to us,' she said.
'Testing different types of drugs and getting as many shots on target is important.'
She said: 'Repurposed drugs have already been demonstrated to be safe for use in humans development of new drugs for different diseases is a long process.
'What essentially bringing repurposed drugs does, is help to accelerate the drug development pipeline – it could save between five and 10 years within that process, compared to taking a new drug through clinical trials for the very first time.'
Helen Matthews, chief executive of Cure Parkinson's, said the iLCT was originally set up to identify drugs that can potentially 'slow down, stop or reverse Parkinson's'.
She added: 'It was through this programme that we realised that there were so many drugs that were also being looked at in the dementia field and there were commonalities there in terms of the drugs looking to reduce inflammation, or whatever it might be, there were specific pathways that those drugs were working on that could be beneficial for both disease areas.
'So given that we were already doing the (work) every year, it made sense to join forces in this way, just to add efficiencies.
'Because if you're looking at the same drugs, we'll only do that digging once, you know, only do that compilation of the dossiers once, so that you can actually take the learning for both diseases and then actually look and see which might be beneficial.'
She said that the 'sharing of knowledge and digging' could also be shared with other disease areas, such as MS.
And on lecanemab and donanemab, Dr Scales added: '(These) were the first disease-targeting therapies that have been licensed in the UK, but obviously are not available on the NHS at the moment.
'They showed for the very first time that we were able to alter the course of the disease.
'And what we're looking forward to now is what the next generation of treatments can bring us and how we can target different parts of the disease.'
Dr Lucy Devendra, head of research at Alzheimer's Society, said: 'Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker.
'Although it is still early days, it's encouraging to see a renewed focus on this type of research and development.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Argus
2 hours ago
- South Wales Argus
Concern over weight gain after ‘skinny jabs'
Research shows that many people regain weight after stopping treatment if they are not supported, the National Institute for Health and Care Excellence (Nice) said. The health watchdog said that people coming off the drugs should be offered 'structured advice and follow-up support' to help prevent weight gain. The guidance is for people who are offered the treatments through the NHS. An estimated 1.5 million people are taking weight loss jabs in the UK, but the vast majority are paying for them privately so will not be eligible for NHS support after they have finished their treatment. Around 240,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide, through the NHS over the next three years. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. Little swaps can make tasty, healthy changes. For lots of tips and support to eat better visit: — NHS Blackpool Teaching Hospitals 💙🌈 (@BlackpoolHosp) April 12, 2025 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: 'Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'
Leader Live
2 hours ago
- Leader Live
Concern over weight gain after ‘skinny jabs'
Research shows that many people regain weight after stopping treatment if they are not supported, the National Institute for Health and Care Excellence (Nice) said. The health watchdog said that people coming off the drugs should be offered 'structured advice and follow-up support' to help prevent weight gain. The guidance is for people who are offered the treatments through the NHS. An estimated 1.5 million people are taking weight loss jabs in the UK, but the vast majority are paying for them privately so will not be eligible for NHS support after they have finished their treatment. Around 240,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide, through the NHS over the next three years. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. Little swaps can make tasty, healthy changes. For lots of tips and support to eat better visit: — NHS Blackpool Teaching Hospitals 💙🌈 (@BlackpoolHosp) April 12, 2025 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: 'Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'
Powys County Times
2 hours ago
- Powys County Times
Concern over weight gain after ‘skinny jabs'
Health chiefs have raised concerns about people regaining weight after using Wegovy and Mounjaro, saying that patients coming off the drugs should be given support to help prevent them piling on the pounds again. Research shows that many people regain weight after stopping treatment if they are not supported, the National Institute for Health and Care Excellence (Nice) said. The health watchdog said that people coming off the drugs should be offered 'structured advice and follow-up support' to help prevent weight gain. The guidance is for people who are offered the treatments through the NHS. An estimated 1.5 million people are taking weight loss jabs in the UK, but the vast majority are paying for them privately so will not be eligible for NHS support after they have finished their treatment. Around 240,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide, through the NHS over the next three years. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. Little swaps can make tasty, healthy changes. For lots of tips and support to eat better visit: — NHS Blackpool Teaching Hospitals 💙🌈 (@BlackpoolHosp) April 12, 2025 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: 'Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'
